Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Aerobic vaginitis was treated by using Baofukang Suppository 7 days group or Baofukang Suppository 14 days group.To evaluate the efficacy and safety after treatment.
Aerobic vaginitis was treated by using Baofukang Suppository 7 days group or Baofukang Suppository 14 days group.
Group 1: Baofukang Suppository (1.74g), for vaginal use, 2 capsules per night for 7 days.
Group 2: Baofukang Suppository (1.74g), for vaginal use, 2 capsules per night for 14 days.
The efficacy and safety will be evaluated 7~14 days after treatment and 35~42 days after treatment.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Baofukang Suppository 7 days | Experimental | Baofukang Suppository (1.74g), for vaginal external use, 2 capsules per night for 7 days |
|
| Baofukang Suppository 14 days | Experimental | Baofukang Suppository (1.74g), for vaginal external use, 2 capsules per night for 14days |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Experimental: Baofukang Suppository 7 days | Drug | Experimental: Baofukang Suppository 7 days |
|
| Measure | Description | Time Frame |
|---|---|---|
| Cure rate | A vaginal smear composite Donders score of 1 to 2 represents normality. A score of more than 2 is aerobic vaginitis. There are four variables(Lactobacillary; leucocytes; toxic leukocytes; parabasal cells; background flora). Detail see references Links. | First week after treatment |
| Cure rate | A vaginal smear composite Donders score of 1 to 2 represents normality. A score of more than 2 is aerobic vaginitis. There are four variables(Lactobacillary; leucocytes; toxic leukocytes; parabasal cells; background flora).Detail see folowing references. | First month after the treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Side affect | Number of Participants Experiencing AEs Following the First Dose of the Study Product | First week after treatment |
Not provided
Inclusion Criteria:
Aerobic vaginitis diagnosed based on present :
Exclusion Criteria:
Women with sexual activity
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Ping Liu, M.D. | Contact | 86755-83923333 | 5505 | 253783006@qq.com |
| Yiheng Liang, M.D. | Contact | 86755-83923333 | 5518 | 13510331823@163.com |
| Name | Affiliation | Role |
|---|---|---|
| Shangrong Fan, M.D. | Dept of Obstetrics and Gynecology,Peking University Shenzhen Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Peking University Shenzhen Hosptal | Recruiting | Shenzhen | Guangdong | 518036 | China |
Not provided
| Label | URL |
|---|---|
| AV diagnosis and outcome Measure | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D014627 | Vaginitis |
| ID | Term |
|---|---|
| D014623 | Vaginal Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Experimental: Baofukang Suppository 14 days | Drug | Experimental: Baofukang Suppository 14 days |
|
|
| D000091642 | Urogenital Diseases |
| D000091662 | Genital Diseases |